Pembrolizumab-induced mucositis in a patient with recurrent hypopharynx squamous cell cancer.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 31074845.
- Also identified by DOI 10.1002/lary.28038.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pembrolizumab, an anti-PD-1 checkpoint inhibitor, is used in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who have received prior therapy with a platinum-based regimen. As a monotherapy, it is generally well tolerated, but a small percentage of patients may develop immune-mediated inflammatory reactions. We report a case of mucositis and laryngeal edema in a patient on pembrolizumab and review the literature. Laryngoscope, 130:E140-E143, 2020.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Immunological
- Hypopharyngeal Neoplasms
- Mucositis
- Squamous Cell Carcinoma of Head and Neck